Scientific & Clinical Advisory Board
Jeff Weitz, M.D.
Dr. Weitz is Professor of Medicine and Biochemistry and Biomedical Sciences at McMaster University, Executive Director of the Thrombosis and Atherosclerosis Research Institute and President of Council for the International Society on Thrombosis and Haemostasis. Board Certified in Internal Medicine, Hematology and Medical Oncology, Dr. Weitz focuses his clinical practice on patients with thrombotic disorders. His research spans the spectrum from basic studies in the biochemistry of blood coagulation and fibrinolysis to animal models of thrombosis and on to clinical trials of antithrombotic therapy. The breadth of his work is highlighted by his over 600 publications in journals as diverse as the Journal of Clinical Investigation, Journal of Biological Chemistry, Biochemistry, Circulation, Blood, Annals of Internal Medicine, New England Journal of Medicine and Lancet, and 65 book chapters. The recipient of numerous awards, Dr. Weitz is a Fellow of the American Heart Association, the Royal Society of Canada, and the Canadian Academy of Health Sciences.
Thomas Lecompte, M.D.
Dr. Lecompte is associate physician in the Hospital Department of Medicine and Full Professor in the Academic Department of Medicine at the University of Geneva. Since the beginning of his scientific carrier Dr. Lecompte has been interested in haemostasis and more specifically in blood platelets. His first paper of basic research was on phospholipid metabolism in platelets and was published as a Letter in Nature. Dr. Lecompte has been since them interested in inherited platelet disorders – and the way to investigate them, including extracellular vesicles. Dr. Lecompte has conducted research on the so-called antiphospholipid antibodies and on acquired haemostatic disturbances in complex settings associated with a thrombotic risk (COVID-19; post-vaccine thrombosis and thrombocytopenia; haematological malignancies such as essential thrombocythaemia and multiple myeloma; liver cirrhosis); on the phenotyping of primary haemostasis under flow conditions and of the blood coagulation system by means of thrombin generation assays; on the pharmacology of haemostasis (with special interest in laboratory testing for patients receiving antiplatelet agents and anticoagulant, including parenteral direct thrombin inhibitors; on transfusion products with haemostatic properties; and on heparin-induced thrombocytopenia).
François Pattou, M.D.
Dr. Pattou entered as a student at the Faculty of Medicine of Lille in 1984 and became Professor of General Surgery there in 2002, then Head of the Department of General and Endocrine Surgery at the CHRU of Lille in 2006. Since 2001, Dr. Pattou has directed the UMR 859 “Biotherapies for diabetes”, a research team accredited by INSERM and LABEX EGID (European genomic institute for diabetes). For 20 years, his research has focused on the development of new interventional treatments for diabetes and metabolic diseases, and more particularly on cell therapy and metabolic surgery. François Pattou has obtained as Principal Investigator more than 30 research contracts with French (PIA, PHRC, ANR) and international (FP7, IMI, JDRF) institutional partners. This research has given rise to more than 500 international publications. Dr. Pattou also received a grand prize from the Academy of Medicine for his work on cell therapy in diabetes. He coordinates the RHU Precinash project and several clinical trials for the surgical treatment of type 2 diabetes and obesity.
Cedric Hermans, M.D., Ph.D., FRCP (Lon, Edin)
Prof. Hermans currently heads the Division of Haematology, the Hemostasis and Thrombosis Unit as well as the Hemophilia Center of the Saint-Luc University Hospital in Brussels, Belgium. He was appointed Associate Professor at the Medical School of the Catholic University of Louvain in 2003, Full Professor in 2012 and Vice-Dean in 2015. Prof. Hermans has (co)-authored more than 275 original articles in international journals and is a member of several scientific societies and international advisory boards and collaborative research projects. He was president of EAHAD and is currently member of the Board of Directors of the World Federation of Haemophilia and the Editor-in-Chief of the Haemophilia Journal. His main research interests lie in the area of haemostasis and thrombosis, especially clinical studies on the treatment modalities and the wide spectrum of complications of haemophilia in both developed and developing countries, as well as new anticoagulants and the management of thrombosis.
Christophe Dubois, Ph.D.
Prof. Dubois studied biotechnology and cell biology at the university of Marseille, France. During his PhD he worked at Hoffmann-La Roche, Basel, Switzerland in the Dr Beat Steiner’s group. He obtained his PhD at the university of Marseille in 2003. Then he moved to the United States in the Dr. Barbara and Bruce Furie’s lab at Boston, MA. Back to France, between 2006 and 2015 he held a position of Associate Professor at the Faculty of Medicine in Marseille. In 2015, he joined the Faculty of Pharmacy, Aix Marseille University, as Professor of Cell Biology. His research activities are mainly focused on the mechanisms involved in thrombus formation and in thrombosis associated with cancer. He was elected member of the INSERM Scientific specialized committee (2009-2012), member of the council of the French Group on thrombosis and Cancer (2011-2016) and member of the council of the French Group for Thrombosis & Haemostasis (2013). Since 2017, he is co-chair of the Scientific and Standardization Committee on Hemostasis and malignancy from the International Society of Thrombosis and Hemostasis.
Denis Vivien, Ph.D.
Dr. Vivien is Professor and hospital practitioner in Cell Biology, head of the Inserm unit UMR-S U1237 (“physiopathology and Imaging of Neurological Disorders”, PhIND), Scientific director of the Institute Blood and Brain @ Caen-Normandie (BB@C, Inserm, Unicaen, CHU Caen), responsible of the research axis Heart and Brain at the Caen Hospital and of the center for biological resources of the department for clinical research of Caen University Hospital. His lab is a leading group in the field of experimental stroke and on the coordination of clinical trials. Dr. Vivien is also Scientific Advisor for the CRO Strok@lliance through which he offers his laboratory’s expertise and know-how to the pharmaceutical industry, in a bid to accelerate innovative drug development from bench-to-bedside.
Thomas Marichal, Ph.D.
Prof. Marichal is trained as a Veterinary Doctor and obtained a PhD in Immunology from Liege University, Belgium. He then performed a postdoctoral training at Stanford University School of Medicine before being appointed as a permanent researcher from the F.R.S.-FNRS at Liege University. His research has made major contributions in understanding the mechanisms by which allergic type 2 immunity is orchestrated upon exposure to pro-allergic environmental factors, and how allergic type 2 immunity can be prevented. Moreover, he has discovered a beneficial function of allergic type 2 immunity in host defense against toxins. His research currently focuses on lung tissue biology during homeostasis and in the context of lung chronic inflammatory diseases by exploring the relationships existing between structural and myeloid cells that mediate tissue- and context-specific functions.